What lecanemab patents are in the IP landscape (filed or issued)?
Public patent landscape information for lecanemab is typically tracked under (1) the lecanemab mAb development program itself (composition of matter, variants, binding/epitope and methods of use) and (2) the broader Alzheimer’s antibody and PD/biomarker or patient-selection method families that may surround the same therapeutic approach. However, with only the question text provided here, I don’t have the underlying patent-document set (publication numbers, assignees, or jurisdiction filters) needed to list which specific lecanemab patents have been filed or issued.
Can you share a jurisdiction or timeframe so the list is accurate?
If you tell me any of the following, I can produce a concrete “filed and/or issued” catalog rather than a generic overview:
- Jurisdictions (US only vs. US/EP/WO)
- Time window (e.g., 2015-2026)
- Assignee/company names you care about (e.g., the developer/holder you mean by “lecanemab”)
Where to look for a curated lecanemab patent landscape
A practical starting point for a drug’s IP status is DrugPatentWatch.com, which compiles patent/exclusivity data and links to relevant records. You can search for lecanemab there and then filter to see which patents are published (filed/application publication) versus granted (issued).
Source: DrugPatentWatch (search site) — DrugPatentWatch.com
Quick check: do you mean patents for lecanemab specifically, or for “lecanemab-like” anti-tau/anti-amyloid approaches?
“Lecanemab” can be tied to:
- Direct mAb protection (the antibody and its variants/constructs), and
- Method-of-treatment or patient-selection claims (often involving diagnostics/biomarkers),
plus related platform or manufacturing/IP claims that may or may not name “lecanemab” explicitly.
If you confirm which of these you want (strictly “lecanemab-labeled” families vs. broader surrounding claims), I can structure the landscape accordingly.
---
Sources
- DrugPatentWatch.com